Heparin-induced thrombocytopenia in intensive care patients
Research article published in Seminars in thrombosis and hemostasis (2008)
Abstract
Heparin-induced thrombocytopenia (HIT) is a serious, prothrombotic, immune-mediated complication of heparin therapy that can cause limb- and life-threatening thromboembolic events. Prompt diagnosis and therapeutic dose anticoagulation by an alternative anticoagulant are crucial to improve clinical outcome. In critically ill patients, the diagnosis of HIT is difficult due to the high incidence of thrombocytopenia, often caused by reasons other than HIT, and the high incidence of clinically irrelevant, non-platelet-activating anti-PF4-heparin antibodies. Also, treatment of HIT is problematic in these patients. No antidote is available for any of the alternative anticoagulants, and their half-lives are often prolonged in the presence of renal or hepatic insufficiency. This increases the risk of bleeding complications and mandates careful balancing of both risks, thrombosis and bleeding. Therefore, accurate diagnosis of HIT and individual choice of alternative anticoagulant are important for the adequate management of critically ill HIT patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This review examines heparin-induced thrombocytopenia (HIT) in intensive care patients, describing it as a serious, prothrombotic, immune-mediated complication of heparin in which prompt diagnosis and switching to an alternative (non-heparin) anticoagulant are crucial, while noting that diagnosis is hard in the critically ill and that no antidote exists for the alternative agents. The relevance to hirudotherapy is conceptual and historical: HIT is the textbook clinical situation where heparin must be abandoned in favor of a direct thrombin inhibitor, and recombinant hirudin derived from the medicinal leech secretome (lepirudin) was one of the early non-heparin anticoagulants developed for exactly this niche, illustrating how leech biochemistry seeded a clinical drug class. As a caveat, the abstract concerns management of a heparin drug reaction and the conventional alternative anticoagulants; it does not study or endorse medicinal-leech therapy, and being a review it summarizes others' findings rather than presenting new data.
Citation
Heparin-induced thrombocytopenia in intensive care patients.
Selleng K et al. · Seminars in thrombosis and hemostasis, 2008
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026